학술논문
278 PRIMARY RESULTS OF A PHASE 1 MULTICENTER OPEN-LABEL STUDY OF ANTOLIMAB, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS AND ELEVATED GASTRIC AND/OR DUODENAL MAST CELLS
Document Type
Abstract
Author
Source
In Gastroenterology May 2020 158(6) Supplement 1:S
Subject
Language
ISSN
0016-5085